Please enable JavaScript to continue using this application.

Compare $RNA vs $VYGR | Chartloom

Compare

$RNA vs $VYGR

Atrium Therapeutics Inc · Voyager Therapeutics Inc

RNA

Atrium Therapeutics Inc

VYGR

Voyager Therapeutics Inc

Compare $RNA vs $VYGR

Comparing Atrium Therapeutics Inc and Voyager Therapeutics Inc

RNAAtrium Therapeutics Inc

VYGRVoyager Therapeutics Inc

RNAAtrium Therapeutics Inc

Market cap

$144M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

22.0%

YTD performance

-88.3%

52W performance

-82.6%

FCF yield

-55.5%

VYGRVoyager Therapeutics Inc

Market cap

$148M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.33x

Rev growth (TTM)

-19.1%

YTD performance

-39.2%

52W performance

-53.6%

FCF yield

-82.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RNA

VYGR

Detailed metrics comparison

RNA

Atrium Therapeutics Inc

VYGR

Voyager Therapeutics Inc

Market Cap

RNA$144M

VYGR$148M

Enterprise Value

RNA$71M

VYGR$112M

Price

RNA$8.40

VYGR$2.45

P/E Ratio

RNAN/A

VYGRN/A

P/S Ratio

RNA3.48x

VYGR4.30x

EV/Sales

RNA1.73x

VYGR3.26x

EV/EBITDA

RNA0.00x

VYGR8.61x

P/B Ratio

RNA0.63x

VYGR1.01x

P/FCF Ratio

RNAN/A

VYGRN/A

EV/FCF

RNA-0.89x

VYGR-0.92x

PEG Ratio

RNAN/A

VYGRN/A

Forward P/E (NTM)

RNAN/A

VYGRN/A

Forward P/S (NTM)

RNAN/A

VYGR5.33x

Revenue (TTM)

RNA$41M

VYGR$34M

Revenue Growth (YoY)

RNA22.0%

VYGR-19.1%

Forward Rev Growth

RNA-94.2%

VYGR129.7%

Gross Margin (TTM)

RNA0.0%

VYGR0.0%

Operating Margin (TTM)

RNA0.0%

VYGR0.0%

EBITDA Margin (TTM)

RNA-215.0%

VYGR-329.0%

Net Margin (TTM)

RNA-209.2%

VYGR-312.6%

FCF Margin (TTM)

RNA-193.4%

VYGR-352.4%

Net Income (TTM)

RNA$-86M

VYGR$-108M

FCF (TTM)

RNA$-80M

VYGR$-121M

EPS (TTM)

RNA-$5.05

VYGR-$1.78

ROE (TTM)

RNA-4030.0%

VYGR-5792.0%

ROA (TTM)

RNA-5864.0%

VYGR-4500.0%

ROIC (TTM)

RNA-4433.7%

VYGR-5792.0%

Cash

RNA$72M

VYGR$36M

Debt

RNA$0

VYGR$0

Net Cash/Debt

RNA$72M

VYGR$36M

Current Ratio (TTM)

RNA8.73x

VYGR7.51x

Quick Ratio (TTM)

RNA8.59x

VYGR7.16x

Debt/Equity (TTM)

RNA0.00x

VYGR0.00x

Debt/Assets (TTM)

RNA0.0%

VYGR0.0%

Interest Coverage (TTM)

RNAN/A

VYGRN/A

Net Debt/EBITDA (TTM)

RNA0.00x

VYGR0.00x

Beta

RNA1.20

VYGR1.11

52W Performance

RNA-82.6%

VYGR-53.6%

YTD Performance

RNA-88.3%

VYGR-39.2%

% from 52W High

RNA-88.5%

VYGR-55.9%

% from 52W Low

RNA10.1%

VYGR5.2%

Asset Turnover (TTM)

RNA0.28x

VYGR0.14x

FCF Yield (TTM)

RNA-55.5%

VYGR-82.0%

Earnings Yield (TTM)

RNA-60.1%

VYGR-72.8%

Dividend Yield (TTM)

RNAN/A

VYGRN/A

Rule of 40

RNA-171.3

VYGR-371.4

EV/GP/RG

RNAN/A

VYGRN/A

Ticker research

View RNA research View VYGR research

Metric	RNA Atrium Therapeutics Inc	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$144M	$148M
Enterprise Value	$71M	$112M
Price	$8.40	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	3.48x	4.30x
EV/Sales	1.73x	3.26x
EV/EBITDA	0.00x	8.61x
P/B Ratio	0.63x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.89x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.33x
Revenue & Growth
Revenue (TTM)	$41M	$34M
Revenue Growth (YoY)	22.0%	-19.1%
Forward Rev Growth	-94.2%	129.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-215.0%	-329.0%
Net Margin (TTM)	-209.2%	-312.6%
FCF Margin (TTM)	-193.4%	-352.4%
Net Income (TTM)	$-86M	$-108M
FCF (TTM)	$-80M	$-121M
EPS (TTM)	-$5.05	-$1.78
ROE (TTM)	-4030.0%	-5792.0%
ROA (TTM)	-5864.0%	-4500.0%
ROIC (TTM)	-4433.7%	-5792.0%
Financial Health
Cash	$72M	$36M
Debt	$0	$0
Net Cash/Debt	$72M	$36M
Current Ratio (TTM)	8.73x	7.51x
Quick Ratio (TTM)	8.59x	7.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.11
52W Performance	-82.6%	-53.6%
YTD Performance	-88.3%	-39.2%
% from 52W High	-88.5%	-55.9%
% from 52W Low	10.1%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.28x	0.14x
FCF Yield (TTM)	-55.5%	-82.0%
Earnings Yield (TTM)	-60.1%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-171.3	-371.4
EV/GP/RG	N/A	N/A
Ticker research	View RNA research	View VYGR research

Valuation

P/S Ratio

RNA

3.48x

VYGR

4.30x

EV/FCF

VYGR

-0.92x

RNA

-0.89x

Growth & revenue

Revenue Growth TTM

RNA

22.0%

VYGR

-19.1%

Forward Revenue Growth

VYGR

129.7%

RNA

-94.2%

Profitability & performance

Gross Margin

RNA

0.0%

VYGR

0.0%

ROE

RNA

-4030.0%

VYGR

-5792.0%

FCF Yield %

RNA

-55.5%

VYGR

-82.0%

52-Week Performance

VYGR

-53.6%

RNA

-82.6%

Detailed metrics comparison

RNA

Atrium Therapeutics Inc

VYGR

Voyager Therapeutics Inc

Market Cap

RNA$144M

VYGR$148M

Enterprise Value

RNA$71M

VYGR$112M

Price

RNA$8.40

VYGR$2.45

P/E Ratio

RNAN/A

VYGRN/A

P/S Ratio

RNA3.48x

VYGR4.30x

EV/Sales

RNA1.73x

VYGR3.26x

EV/EBITDA

RNA0.00x

VYGR8.61x

P/B Ratio

RNA0.63x

VYGR1.01x

P/FCF Ratio

RNAN/A

VYGRN/A

EV/FCF

RNA-0.89x

VYGR-0.92x

PEG Ratio

RNAN/A

VYGRN/A

Forward P/E (NTM)

RNAN/A

VYGRN/A

Forward P/S (NTM)

RNAN/A

VYGR5.33x

Revenue (TTM)

RNA$41M

VYGR$34M

Revenue Growth (YoY)

RNA22.0%

VYGR-19.1%

Forward Rev Growth

RNA-94.2%

VYGR129.7%

Gross Margin (TTM)

RNA0.0%

VYGR0.0%

Operating Margin (TTM)

RNA0.0%

VYGR0.0%

EBITDA Margin (TTM)

RNA-215.0%

VYGR-329.0%

Net Margin (TTM)

RNA-209.2%

VYGR-312.6%

FCF Margin (TTM)

RNA-193.4%

VYGR-352.4%

Net Income (TTM)

RNA$-86M

VYGR$-108M

FCF (TTM)

RNA$-80M

VYGR$-121M

EPS (TTM)

RNA-$5.05

VYGR-$1.78

ROE (TTM)

RNA-4030.0%

VYGR-5792.0%

ROA (TTM)

RNA-5864.0%

VYGR-4500.0%

ROIC (TTM)

RNA-4433.7%

VYGR-5792.0%

Cash

RNA$72M

VYGR$36M

Debt

RNA$0

VYGR$0

Net Cash/Debt

RNA$72M

VYGR$36M

Current Ratio (TTM)

RNA8.73x

VYGR7.51x

Quick Ratio (TTM)

RNA8.59x

VYGR7.16x

Debt/Equity (TTM)

RNA0.00x

VYGR0.00x

Debt/Assets (TTM)

RNA0.0%

VYGR0.0%

Interest Coverage (TTM)

RNAN/A

VYGRN/A

Net Debt/EBITDA (TTM)

RNA0.00x

VYGR0.00x

Beta

RNA1.20

VYGR1.11

52W Performance

RNA-82.6%

VYGR-53.6%

YTD Performance

RNA-88.3%

VYGR-39.2%

% from 52W High

RNA-88.5%

VYGR-55.9%

% from 52W Low

RNA10.1%

VYGR5.2%

Asset Turnover (TTM)

RNA0.28x

VYGR0.14x

FCF Yield (TTM)

RNA-55.5%

VYGR-82.0%

Earnings Yield (TTM)

RNA-60.1%

VYGR-72.8%

Dividend Yield (TTM)

RNAN/A

VYGRN/A

Rule of 40

RNA-171.3

VYGR-371.4

EV/GP/RG

RNAN/A

VYGRN/A

Ticker research

View RNA research View VYGR research

Metric	RNA Atrium Therapeutics Inc	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$144M	$148M
Enterprise Value	$71M	$112M
Price	$8.40	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	3.48x	4.30x
EV/Sales	1.73x	3.26x
EV/EBITDA	0.00x	8.61x
P/B Ratio	0.63x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.89x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.33x
Revenue & Growth
Revenue (TTM)	$41M	$34M
Revenue Growth (YoY)	22.0%	-19.1%
Forward Rev Growth	-94.2%	129.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-215.0%	-329.0%
Net Margin (TTM)	-209.2%	-312.6%
FCF Margin (TTM)	-193.4%	-352.4%
Net Income (TTM)	$-86M	$-108M
FCF (TTM)	$-80M	$-121M
EPS (TTM)	-$5.05	-$1.78
ROE (TTM)	-4030.0%	-5792.0%
ROA (TTM)	-5864.0%	-4500.0%
ROIC (TTM)	-4433.7%	-5792.0%
Financial Health
Cash	$72M	$36M
Debt	$0	$0
Net Cash/Debt	$72M	$36M
Current Ratio (TTM)	8.73x	7.51x
Quick Ratio (TTM)	8.59x	7.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.11
52W Performance	-82.6%	-53.6%
YTD Performance	-88.3%	-39.2%
% from 52W High	-88.5%	-55.9%
% from 52W Low	10.1%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.28x	0.14x
FCF Yield (TTM)	-55.5%	-82.0%
Earnings Yield (TTM)	-60.1%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-171.3	-371.4
EV/GP/RG	N/A	N/A
Ticker research	View RNA research	View VYGR research